Sinus Node Dysfunction
Definition
Sinus node dysfunction (SND), historically called sick sinus syndrome, encompasses a spectrum of abnormalities in sinoatrial impulse formation and propagation: sinus bradycardia (<50 bpm), ectopic atrial bradycardia, sinoatrial exit block, sinus pause (>3 s), sinus node arrest, and tachy-brady syndrome. Chronotropic incompetence (failure to reach 80% of expected heart rate reserve with exertion) is also a manifestation. Diagnosis requires both bradycardia and symptoms; the presence of sinus bradycardia or a pause >3 s alone is insufficient.
Key Concepts
Epidemiology
- Most common in patients in their 70s–80s; incidence mirrors pacemaker implantation for AV nodal disease (both age-dependent)
- Frequent comorbidities: ischemic heart disease, HF, valvular disease, cerebrovascular disease, AF (sources/bradycardia-acc-aha-hrs-2018, very high)
- Asymptomatic sinus bradycardia is NOT associated with adverse outcomes
- Symptomatic SND: high risk of syncope, AF, and HF; chronotropic incompetence associated with increased CV death and overall mortality (sources/bradycardia-acc-aha-hrs-2018, very high)
Pathophysiology
- Age-dependent progressive degenerative fibrosis of the sinoatrial nodal tissue and surrounding atrial myocardium → abnormal impulse formation and propagation (sources/bradycardia-acc-aha-hrs-2018, very high)
- Same fibrotic milieu responsible for atrial arrhythmias → tachy-brady syndrome (alternating bradycardia and AF/atrial flutter/atrial tachycardia)
- Sinus node fibrosis is associated with fibrosis in the AV node → SND patients can develop AV block over time (3–35% risk at 5 years after atrial PPM implantation)
- Collagen content increases with age → slower heart rate and longer sinoatrial conduction times (SACT)
- Extrinsic/secondary SND: acute MI, electrolyte abnormalities, hypothyroidism, medications (beta-blockers, calcium channel blockers, digoxin, antiarrhythmics), Lyme carditis, vagal tone
Clinical Presentation
- Symptoms range from mild fatigue to frank syncope; severity correlates with heart rate or pause duration
- Syncope present in 50% of patients who received PPM for SND in one RCT (sources/bradycardia-acc-aha-hrs-2018, very high)
- Other symptoms: dyspnea on exertion (chronotropic incompetence), lightheadedness, chronic fatigue
- Symptom–bradycardia temporal correlation is the gold standard of diagnosis
- Tachy-brady syndrome: most disabling feature is recurrent syncope/presyncope from asystolic pause after termination of paroxysmal AF
Definitions
| Term |
Definition |
| Sinus bradycardia |
Sinus rate <50 bpm |
| Sinus pause |
Sinus node depolarizes >3 s after last atrial depolarization |
| Sinoatrial exit block |
Blocked conduction between sinus node and atrial tissue |
| Tachy-brady syndrome |
Sinus bradycardia/pause alternating with atrial tachyarrhythmias (AF/flutter) |
| Chronotropic incompetence |
Failure to reach 80% of expected heart rate reserve ([220−age] − resting HR) during exercise |
Evaluation
- Comprehensive history and physical examination: symptom timing, triggers, medications, family history
- 12-lead ECG: Class I
- Ambulatory ECG: duration selected based on symptom frequency (24–48h Holter → extended external monitor → ICM)
- Sleep apnea evaluation: treating OSA reduces frequency of nocturnal bradycardia; nocturnal bradycardia is NOT in itself an indication for PPM
- LBBB on ECG → echocardiography to exclude structural heart disease
- ICM (implantable cardiac monitor): for infrequent/unexplained syncope undiagnosed by non-invasive means (Class IIa)
- EPS: limited role in SND; can measure sinus node recovery time (SNRT) and SACT; normal values do not exclude SND
Acute Management
- Evaluate and treat reversible causes (Class I, C-EO): medications, electrolytes, MI, thyroid, infection
- Atropine (Class IIa, B-NR): for symptomatic/hemodynamically significant bradycardia; NOT effective after cardiac transplantation
- Beta-agonists (dopamine, isoproterenol, epinephrine): for refractory bradycardia unresponsive to atropine (Class IIa)
- Theophylline/aminophylline (Class IIb): for refractory bradycardia unresponsive to atropine
- Temporary pacing (Class I): transcutaneous → transvenous for hemodynamically significant bradycardia unresponsive to medical therapy
Permanent Pacing Indications
| COR |
LOE |
Indication |
| I |
C-LD |
Symptoms directly attributable to SND |
| I |
C-EO |
Symptomatic sinus bradycardia from essential GDMT with no alternative treatment |
| IIa |
C-EO |
Tachy-brady syndrome with symptoms attributable to bradycardia |
| IIa |
C-EO |
Symptomatic chronotropic incompetence (with rate-responsive programming) |
| IIb |
C-LD |
Trial of oral theophylline to predict pacing response |
- No established minimum HR or pause duration for PPM in SND; symptom–bradycardia temporal correlation is the key determinant
- Primary benefit: QOL improvement (not mortality)
- Direct temporal correlation is the gold standard and confers highest likelihood of response to pacing therapy
Pacing Mode for SND
| COR |
LOE |
Recommendation |
| I |
B-R |
Atrial-based pacing (AAI or DDD) over VVI — reduces new-onset AF |
| I |
B-R |
Dual chamber or single-chamber atrial pacing if intact AV conduction without conduction abnormalities |
| IIa |
B-R |
Program DDD to minimize ventricular pacing if intact AV conduction |
| IIa |
C-EO |
VVI reasonable if frequent ventricular pacing not expected or significant comorbidities |
- Four RCTs (PASE, MOST, CTOPP, UKPACE): atrial-based pacing reduces new AF vs VVI; no mortality, stroke, or HF hospitalization difference
- Single-chamber VVI can cause pacemaker syndrome (uncoupled AV contraction, valvular regurgitation, chronic fatigue, dyspnea, symptomatic hypotension)
- Risk of AV block developing after atrial PPM: 3–35% at 5 years → DDD generally preferred over AAI unless very low risk of AV block
Contradictions / Open Questions
- Pathophysiologic link between SND and AF (tachy-brady syndrome) remains incompletely understood — is AF a cause or consequence of SND or a shared fibrotic substrate? Active area of investigation (sources/bradycardia-acc-aha-hrs-2018, very high)
- Rate-responsive pacing in SND: one RCT showed no benefit vs fixed-rate DDD pacing; confounded by high RV pacing percentage (>90%), which may have offset any rate-responsive benefit
- Ablation of AF (atrial tachyarrhythmia) in tachy-brady syndrome may obviate need for PPM — evidence from non-randomized observational data only
- Optimal monitoring duration and method for symptom-rhythm correlation remains individualized; no standardized protocol proven superior
Connections
Sources